Enterprise Value
454.1M
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
0.03%
Insider Ownership
0.00%
Institutional Own.
3.57%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TARPEYO (Nefecon) (budesonide) Details IgA nephropathy | Approved Quarterly sales | |
TARPEYO (Nefecon) (budesonide) Details IgA nephropathy | PDUFA Approval decision | |
Setanaxib (NOX1/NOX4 inhibitor) Details Primary biliary cholangitis, Liver disease | Phase 2/3 Data readout | |
Setanaxib (NOX1/NOX4 inhibitor) Details Solid tumor/s, Cancer, Head and neck squamous cell carcinoma | Phase 2 Data readout | |
Setanaxib (NOX1/NOX4 inhibitor) Details Alport Syndrome | Phase 2 Initiation |